Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.
Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg G, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. REDUCE-IT USA: results from the 3,146 patients randomized in the United States.Circulation. 2019; epub ahead of print.
Bhatt DL, Steg PG, Miller M, et al. Reduction in First and Total Ischemic Events with Icosapent Ethyl Across Baseline Triglyceride Tertiles.J Am Coll Cardiol. 2019;74(8):1159-1161.
https://doi.org/10.1016/j.jacc.2019.06.043
Bhatt DL, Steg PG, Miller M. Reply to letters from Chan L-N and from Borghi C, Fogacci F, Cicero AFG. Cardiovascular risk reduction with icosapent ethyl. N Engl J Med. 2019;380:1677-1678.
https://www.nejm.org/doi/pdf/10.1056/NEJMc1902165